Posted by Michael Wonder on 17 Jun 2026
Biogen Canada disappointed by outcome of pan-Canadian Pharmaceutical Alliance negotiations for Skyclarys
16 June 2026 - - Biogen Canada is disappointed that negotiations with the pan-Canadian Pharmaceutical Alliance for Skyclarys (omaveloxolone) have concluded without reaching an agreement.
The closure of negotiations follows assessments from Health Canada, Canada's Drug Agency (CDA-AMC) and Quebec's Institut national d'excellence en santé et en services sociaux (INESSS), which affirmed the therapeutic value of SKYCLARYS, and underscored the significant unmet need faced by people living with Friedreich ataxia in Canada.
